The Wistar Institute of Philadelphia Signs Agreement With DavosPharma


DavosPharma recently announced it has signed a collaborative agreement with The Wistar Institute of Philadelphia. This agreement provides DMPK, and preclinical IND enabling studies and logistical support to advance the development of novel therapeutics for cancers associated with Epstein-Barr virus (EBV), and other diseases. Funding will be supported by a Drug Discovery Award from the Wellcome Trust Institute.

Since 1972, DavosPharma has serviced the pharmaceutical industry, from preclinical development to commercialization. Over the years, the company has established an excellent reputation in evaluating, coordinating, and delivering drug development through strategic partners. DavosPharma is headquartered in Upper Saddle River, NJ, and maintains offices in Research Triangle Park, NC; Pennsylvania Biotechnology Center, Doylestown, PA; San Francisco, CA; San Diego, CA, and Milan, Italy. For more information, visit www.davos.com.

The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the country, Wistar has long held the prestigious Cancer Center designation from the National Cancer Institute. For more information, visit www.wistar.org.